Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Amgen

Bristol-Myers

Eli Lilly

Merck

Pfizer

Sanofi

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.

Investor patience tested as pharmaceutical stocks take a tumble

Shares of Johnson & Johnson NYSE: JNJ slid 4.84% lower the week ending October 27, as the company's subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder.

J&J stock down as business unit mulls talc-related bankruptcy

SAN FRANCISCO--(BUSINESS WIRE)--J&J Ventures Gaming LLC, a leader in gaming and amusements, is unlocking opportunities to fuel revenue growth driven by the SugarCRM platform. Founded in 1929, J&J Gaming provides world-class gaming machines and services to nearly 4,000 businesses nationwide, has more than 25,600 machines in operation, and is one of the fastest-growing companies in the U.S. The company offers unparalleled expertise with a 24/7/365 service team providing the most up-to-dat.

Gaming and Entertainment Leader J&J Ventures Gaming, LLC Unlocks New Sales Opportunities with Sugar Sell AI-Powered Sales Automation

GlaxoSmithKline

British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.

GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy

HARTFORD, Conn.--(BUSINESS WIRE)--At a recent news conference, Sen. Richard Blumenthal, D-Conn., flanked by ovarian cancer victims Lynn Skoda and Joan Kiley, sharply criticized Johnson & Johnson (NYSE: JNJ) for its role in the spread of cancer through its talcum powder products. Ms. Kiley conveyed her emotional story, holding a photograph of her loved ones taken during her chemotherapy for ovarian cancer. Her account emphasized the broad impact of Johnson & Johnson's alleged negligence,.

Cancer Victims Support Sen. Richard Blumenthal in Urging Johnson & Johnson to Accept Responsibility

Apple

Amazon

Bank of America

Chevron

Coca-Cola

Mastercard

Procter & Gamble

Visa

The megacap stocks in Berkshire Hathaway's portfolio include some of Buffett's largest and smallest holdings. Income, growth, and value investors can all find at least one stock to like in the group.

Nearly 70% of Warren Buffett's $326 Billion Portfolio Is Invested in These 9 Megacap Stocks

U.S. Bancorp

Warren Buffett has run absolute circles around the benchmark S&P 500 since becoming Berkshire Hathaway's CEO in 1965. Thanks to an acquisition that occurred in 1998, Buffett's company owns a specialty investment firm that oversees $690 million of invested assets -- i.e.

Warren Buffett's $690 Million Secret Portfolio Is Buying 3 Historically Cheap Stocks

Johnson & Johnson has begun providing documents and information in response to a civil investigation by the U.S. Department of Justice related to free and discounted eye surgery products, the company disclosed in a filing on Friday.

Johnson & Johnson produces documents in DoJ civil investigation of eye products

Church & Dwight

Clorox

Fortis

Kimberly-Clark

McDonald's

MGE Energy

Novartis

PepsiCo

Investors are worried about soaring interest rates, a pending government shutdown, wars around the world, and a recession looming next year. History is very clear, market timing is the WORST thing you can possibly try. None of the best investors in history do it, and neither should you. Dividend aristocrats and low-volatility blue chips are two proven ways to beat the market with lower volatility. Low-volatility aristocrats are the ultimate way to sleep well at night.

10 High-Yield Dividend Aristocrats Perfect For What's Coming Next

Microsoft

Investors have seen it all in the past three years: a pandemic, lockdown, supply chain issues, inflation, war and high interest rates. The market has shown high volatility and put investors in a state where they are only looking to invest in stocks that have already proven themselves and can survive through market turmoil.

3 Stocks to Buy (and Never Ever Sell)

High-quality dividend stocks often deliver market-beating returns for shareholders. In 2023, though, a fair amount of these equities have struggled.

2 Magnificent Dividend Stocks That Could Deliver a Lifetime of Passive Income

Gilead Sciences

Johnson & Johnson is seeing more profitability after its Kenvue spinoff. Amgen's purchase of Horizon Therapeutics will boost its revenue.

3 Pharma Stocks That Are Screaming Buys in October

Verizon

The stock market has entered a slump. The Federal Reserve continues its campaign to limit inflation.

Dow Jones Bear Market: 3 Cheap Stocks to Buy Now

Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates.

Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?

Kellogg

Realty Income Corp

Navigating the thunderstorm of fluctuating markets, savvy investors anchor their portfolios with the best forever stocks. These stocks have proven resilient in the face of economic uncertainties and continue to flourish amid influential megatrends.

The 7 Best Forever Stocks to Buy for October 2023

British American Tobacco

Rising yields on risk-free Treasuries are putting downward pressure on dividend-paying stocks. Johnson & Johnson's dividend payout has grown for 61 consecutive years, but the stock is trading at a lower valuation than we've seen in years.

2 Exceptional Dividend Stocks Near 52-Week Lows. Are They Bargains Now?

Citigroup

Dominion Energy

Duke Energy

Alphabet

UnitedHealth Group

Vanguard Consumer Staples ETF

Technology Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

Bond yields are showing signs that they have peaked. If they keep dropping, it would make a host of stocks look attractive including Duke Energy, Coca-Cola, Procter & Gamble, and Johnson & Johnson.

The Bond Sell-Off Might Be Over. Buy These Stocks to Win.

Alibaba

JD.com

NVIDIA

Earlier this year, the investing world was rocked by the surprising revelation that famed investor Michael Burry had placed a massive bearish bet against the stock market.

What stocks is Michael Burry shorting?

News for Johnson & Johnson Stock (JNJ)